

Ref: FOI/GS/ID 6983

**Please reply to:**  
FOI Administrator  
Trust Management  
Maidstone Hospital  
Hermitage Lane  
Maidstone, Kent  
ME16 9QQ  
Email: [mtw-tr.foiadmin@nhs.net](mailto:mtw-tr.foiadmin@nhs.net)  
[www.mtw.nhs.uk](http://www.mtw.nhs.uk)

08 October 2021

## **Freedom of Information Act 2000**

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to dermatological and rheumatological conditions.

*You asked:*

*Q1. How many patients were treated in August 2021 (or latest available month) by the dermatology department with the following drugs:*

- 1. Baricitinib (Olmiant)*
- 2. Bimekizumab (Bimzelx)*
- 3. Brodalumab (Kyntheum)*
- 4. Dupilumab (Dupixent)*
- 5. Ixekizumab (Taltz)*
- 6. Risankizumab (Skyrizi)*
- 7. Guselkumab (Tremfya)*
- 8. Secukinumab (Cosentyx)*
- 9. Tildrakizumab (Ilumetri)*
- 10. Ustekinumab (Stelara)*

*Q2. How many patients were treated in August 2021 (or latest available month) by the rheumatology department with the following drugs:*

- 1. Baricitinib (Olmiant)*
- 2. Filgotinib (Jyseleca)*
- 3. Guselkumab (Tremfya)*
- 4. Ixekizumab (Taltz)*
- 5. Secukinumab (Cosentyx)*
- 6. Tofacitinib (Xeljanz)*
- 7. Upadacitinib (Rinvoq)*
- 8. Ustekinumab (Stelara)*

Trust response:

Q1. The Trust does not have a dermatology department.

Q2.

1. 4
2. 0
3. 0
4. 0
5. 30
6. 17
7. 0
8. 1